New cyclodextrin-based nanocarriers for drug delivery and phototherapy using an irinotecan metabolite

Einafshar, Elham; Asl, Ali Haghighi; Nia, Azadeh Hashem; Mohammadi, Marzieh; Malekzadeh, Azim; Ramezani, Mohammad

doi:10.1016/j.carbpol.2018.03.102

Cited by 45 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conjugation of α-, β-, and γ-cyclodextrins (CD) to graphene oxide (GO) sheets was achieved by the esterification of carboxyl functional groups of the GO with hydroxyl groups of CD, catalyzed by EDC/DMAP. The reaction produced stable and biocompatible nanocarriers to encapsulate SN38, an active metabolite of irinotecan approved for clinical use in metastatic colorectal cancer, to overcome its solubility and stability issues and reduce its side effects [127]. The synergistic treatment platform was demonstrated to have the potential for colorectal cancer therapeutics.…”

Section: Hydroxyl (R-oh)mentioning

confidence: 99%

Advances in Functionalized Photosensitive Polymeric Nanocarriers

Fernández

Orozco

2021

Polymers

View full text Add to dashboard Cite

The synthesis of light-responsive nanocarriers (LRNs) with a variety of surface functional groups and/or ligands has been intensively explored for space-temporal controlled cargo release. LRNs have been designed on demand for photodynamic-, photothermal-, chemo-, and radiotherapy, protected delivery of bioactive molecules, such as smart drug delivery systems and for theranostic duties. LRNs trigger the release of cargo by a light stimulus. The idea of modifying LRNs with different moieties and ligands search for site-specific cargo delivery imparting stealth effects and/or eliciting specific cellular interactions to improve the nanosystems’ safety and efficacy. This work reviews photoresponsive polymeric nanocarriers and photo-stimulation mechanisms, surface chemistry to link ligands and characterization of the resultant nanosystems. It summarizes the interesting biomedical applications of functionalized photo-controlled nanocarriers, highlighting the current challenges and opportunities of such high-performance photo-triggered delivery systems.

show abstract

Section: Hydroxyl (R-oh)mentioning

confidence: 99%

Advances in Functionalized Photosensitive Polymeric Nanocarriers

Fernández

Orozco

2021

Polymers

View full text Add to dashboard Cite

show abstract

“…After delivery of these agents at the tumor site, local irradiation has resulted in the killing of the cancerous cells and tumor shrinkage. Current research studies are focused on the use of magnetic nanoparticles for targeting or tracking cancer cells by magnetic resonance imaging (MRI) [154,155,156,157].…”

Section: Controlled Drug Delivery Approaches For Oral Cancermentioning

confidence: 99%

Controlled Drug Delivery Systems for Oral Cancer Treatment—Current Status and Future Perspectives

et al. 2019

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC), which encompasses the oral cavity-derived malignancies, is a devastating disease causing substantial morbidity and mortality in both men and women. It is the most common subtype of the head and neck squamous cell carcinoma (HNSCC), which is ranked the sixth most common malignancy worldwide. Despite promising advancements in the conventional therapeutic approaches currently available for patients with oral cancer, many drawbacks are still to be addressed; surgical resection leads to permanent disfigurement, altered sense of self and debilitating physiological consequences, while chemo- and radio-therapies result in significant toxicities, all affecting patient wellbeing and quality of life. Thus, the development of novel therapeutic approaches or modifications of current strategies is paramount to improve individual health outcomes and survival, while early tumour detection remains a priority and significant challenge. In recent years, drug delivery systems and chronotherapy have been developed as alternative methods aiming to enhance the benefits of the current anticancer therapies, while minimizing their undesirable toxic effects on the healthy non-cancerous cells. Targeted drug delivery systems have the potential to increase drug bioavailability and bio-distribution at the site of the primary tumour. This review confers current knowledge on the diverse drug delivery methods, potential carriers (e.g., polymeric, inorganic, and combinational nanoparticles; nanolipids; hydrogels; exosomes) and anticancer targeted approaches for oral squamous cell carcinoma treatment, with an emphasis on their clinical relevance in the era of precision medicine, circadian chronobiology and patient-centred health care.

show abstract

“…So that liver activation is not required, thereby interpatient variability is eliminated [18]. Despite the promising chemotherapeutic effects of SN38, its clinical application is relatively hindered by its very low solubility in pharmaceutically accepted media and little stability in physiological pH [16,19]. To overcome such limitations, studies are moved towards attachment of SN38 to hydrophilic polymeric moieties such as EZN-2208 which is PEGylated SN38 in phase 2 clinical trials [20] or its loading into nanoparticles such as liposomes [21], polymeric micelles (NK012 in phase 1 clinical studies) [22] or carbon nanotubes [23].…”

Section: Introductionmentioning

confidence: 99%

Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38

Alibolandi

Farzad

Mohammadi

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

New integrin-targeted nanoparticles made of chitosan-stabilized PLGA matrix was developed to specifically target colon adenocarcinoma. To this aim, SN38-encapsulated chitosan-coated PLGA NPs were conjugated with tetrac for integrin receptor-guided delivery. To provide a sustained release pattern for SN38, it was loaded into nanoparticles using single emulsion method. The size of NPs were 174.23 ± 6.12 nm with drug encapsulation efficiency and loading content of 73.16 ± 11.15 and 4.45 ± 0.31, respectively. The in vitro results confirmed that the designed nanoplatform showed specific cellular uptake and cytotoxicity in integrin overexpressing cancer cells and provided a sustained release profile for SN38. Additionally, an increased therapeutic potency of targeted formulation over both non-targeted and free drug was shown in vivo.

show abstract

New cyclodextrin-based nanocarriers for drug delivery and phototherapy using an irinotecan metabolite

Cited by 45 publications

References 37 publications

Advances in Functionalized Photosensitive Polymeric Nanocarriers

Advances in Functionalized Photosensitive Polymeric Nanocarriers

Controlled Drug Delivery Systems for Oral Cancer Treatment—Current Status and Future Perspectives

Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38

Contact Info

Product

Resources

About